
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Epidemiology of multiple sclerosis: results from a large observational study in the UK”, J Neurol, vol. 262, pp. 2033-41, 2015.
, “The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK”, J Invest Dermatol, vol. 137, pp. 1240-1247, 2017.
, “A follow-up safety study of ciprofloxacin users”, Pharmacotherapy, vol. 13, pp. 461-4, 1993.
, “Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents”, Diabetes Care, vol. 22, pp. 2067-71, 1999.
, “Glucocorticoid use, other associated factors, and the risk of tuberculosis”, Arthritis Rheum, vol. 55, pp. 19-26, 2006.
, “Hyperlipidaemia and incident osteoarthritis of the hand: a population-based case-control study”, Osteoarthritis Cartilage, vol. 25, pp. 1040-1045, 2017.
, “Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study”, Eur J Neurol, vol. 16, pp. 745-51, 2009.
, “Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis”, Arthritis Care Res (Hoboken), 2018.
, “Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK–a nested case-control analysis”, Diabetes Obes Metab, vol. 16, pp. 801-11, 2014.
, “Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort”, J Neurol, vol. 254, pp. 1736-41, 2007.
, “Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis”, Semin Arthritis Rheum, vol. 46, pp. 650-656, 2017.
, “Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008”, Respiration, vol. 84, pp. 200-6, 2012.
, “Infections in patients diagnosed with multiple sclerosis: A multi-database study”, Mult Scler Relat Disord, vol. 41, p. 101982, 2020.
, “Inflammatory Bowel Disease and the Risk of Autoimmune Diseases”, J Crohns Colitis, vol. 10, pp. 186-93, 2016.
, “Influenza infections and risk of Alzheimer's disease”, Brain Behav Immun, vol. 57, pp. 187-192, 2016.
, “Inhaled corticosteroids and the risk of fractures in children and adolescents”, Pediatrics, vol. 114, pp. 469-73, 2004.
, “Intrauterine device use and the risk of pre-eclampsia: a case-control study”, Bjog, vol. 123, pp. 788-95, 2016.
, “Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide”, Arch Dermatol, vol. 136, pp. 1231-6, 2000.
, “Itraconazole and fluconazole and certain rare, serious adverse events”, Pharmacotherapy, vol. 22, pp. 697-700, 2002.
, “Lifestyle factors, psychiatric and neurologic comorbidities, and drug use associated with incident seizures among adult patients with depression: a population-based nested case-control study”, Eur J Epidemiol, vol. 31, pp. 1113-1122, 2016.
, “Lipid-lowering drugs and the risk of depression and suicidal behavior”, Arch Intern Med, vol. 163, pp. 1926-32, 2003.
, “Lithium, antipsychotics, and risk of psoriasis”, J Clin Psychopharmacol, vol. 29, pp. 134-40, 2009.
, “Live attenuated polio vaccine and the risk of intussusception”, Br J Clin Pharmacol, vol. 52, pp. 451-3, 2001.
, “Liver disease associated with diclofenac, naproxen, and piroxicam”, Pharmacotherapy, vol. 12, pp. 207-12, 1992.
, “Long-term metformin use is associated with decreased risk of breast cancer”, Diabetes Care, vol. 33, pp. 1304-8, 2010.
, “Malaria chemoprophylaxis regimens: a descriptive drug utilization study”, Travel Med Infect Dis, vol. 12, pp. 718-25, 2014.
, “Maternal Pre-pregnancy Body Mass Index and Autism Spectrum Disorder among Offspring: A Population-Based Case-Control Study”, Paediatr Perinat Epidemiol, vol. 30, pp. 479-87, 2016.
, “Metabolic syndrome in relation to Barrett's esophagus and esophageal adenocarcinoma: Results from a large population-based case-control study in the Clinical Practice Research Datalink”, Cancer Epidemiol, vol. 42, pp. 9-14, 2016.
, “Metabolic syndrome in relation to risk of meningioma”, Oncotarget, vol. 8, pp. 2284-2292, 2017.
, “Metformin and the risk of endometrial cancer: a case-control analysis”, Gynecol Oncol, vol. 129, pp. 565-9, 2013.
, “Metformin and the risk of head and neck cancer: a case-control analysis”, Diabetes Obes Metab, vol. 16, pp. 1148-54, 2014.
, “Metformin and the risk of renal cell carcinoma: a case-control analysis”, Eur J Cancer Prev, vol. 26, pp. 257-262, 2017.
, “Metformin does not alter the risk of lung cancer: a case-control analysis”, Lung Cancer, vol. 78, pp. 133-7, 2012.
, “Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study”, J Am Geriatr Soc, vol. 60, pp. 916-21, 2012.
, “Migraine and the risk of stroke, TIA, or death in the UK (CME)”, Headache, vol. 47, pp. 1374-84, 2007.
, “Migraine incidence, comorbidity and health resource utilization in the UK”, Cephalalgia, vol. 28, pp. 57-64, 2008.
, “Migraine, triptans, and the risk of developing rosacea: a population-based study within the United Kingdom”, J Am Acad Dermatol, vol. 69, pp. 399-406, 2013.
, “Mortality of patients with multiple sclerosis: a cohort study in UK primary care”, J Neurol, vol. 261, pp. 1508-17, 2014.
, “No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study”, BMC Cancer, vol. 15, p. 719, 2015.
, “Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors”, Pharmacotherapy, vol. 26, pp. 1379-87, 2006.
, “Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: a cohort study”, Pharmacotherapy, vol. 13, pp. 212-7, 1993.
, “Non-steroidal anti-inflammatory drugs and the risk of head and neck cancer: A case-control analysis”, Int J Cancer, vol. 137, pp. 2424-31, 2015.
, “Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer”, Int J Cancer, vol. 137, pp. 144-53, 2015.
, “NSAID use and risk of Parkinson disease: a population-based case-control study”, Eur J Neurol, vol. 18, pp. 1336-42, 2011.
, “NSAIDs, quinolones and convulsions: An epidemiologic approach”, vol. 6, pp. 119-128, 1992.
, “Oral and inhaled glucocorticoid use and risk of Achilles or biceps tendon rupture: a population-based case-control study”, Ann Med, vol. 47, pp. 492-8, 2015.
, “Parkinson disease and the risk of epileptic seizures”, Ann Neurol, vol. 83, pp. 363-374, 2018.
, “Parkinson's disease or Parkinson symptoms following seasonal influenza”, Influenza Other Respir Viruses, vol. 5, pp. 328-33, 2011.
, “Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database”, Acta Orthop, vol. 83, pp. 653-60, 2012.
, “Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study”, Ann Rheum Dis, vol. 74, pp. 1651-8, 2015.
,